Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iferanserin
- Development stage
- Discontinued
- Lead developer
- Ventrus Biosciences
- Modality
- Small Molecules
- Administration
- Rectal
01
Overview
Iferanserin is a small molecule drug that acts as a selective antagonist of the serotonin 5-HT2A receptor. It was developed primarily as an intra-rectal formulation for the treatment of hemorrhoid disease. The drug reached phase III clinical trials for this indication but development has since been discontinued. Iferanserin was initially developed by Assembly Biosciences and investigated in both the United States and Germany for internal hemorrhoids.
- Other names
- iferanserin [INN]58754-46-4NWR3BEB8PANWR-3BEB8PANWR 3BEB8PA
02
Targets
HTR2A (Serotonin receptor 5-HT2A)
Beyond the preview
Go deeper on iferanserin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iferanserin.